6 O
ADVERSE O
REACTIONS O
EXCERPT O
: O
Most O
commonly O
reported O
adverse O
reactions O
( O
> O
2 O
% O
and O
> O
placebo O
) O
were O
hypertension O
, O
nasopharyngitis O
, O
urinary O
tract O
infection O
and O
headache O
( O
6.1 O
) O
. O

To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Astellas O
Pharma O
US O
, O
Inc O
. O
at O
1-800-727-7003 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
clinical O
practice O
. O

In O
three O
, O
12 O
week O
, O
double-blind O
, O
placebo-controlled O
, O
safety O
and O
efficacy O
studies O
in O
patients O
with O
overactive B-Not_AE_Candidate
bladder I-Not_AE_Candidate
( O
Studies O
1 O
, O
2 O
, O
and O
3 O
) O
, O
MYRBETRIQ O
( O
r O
) O
was O
evaluated O
for O
safety O
in O
2736 O
patients O
[ O
see O
Clinical O
Studies O
( O
14 O
) O
] O
. O

Study O
1 O
also O
included O
an O
active O
control O
. O

For O
the O
combined O
Studies O
1 O
, O
2 O
, O
and O
3 O
, O
432 O
patients O
received O
MYRBETRIQ O
( O
r O
) O
25 O
mg O
, O
1375 O
received O
MYRBETRIQ O
( O
r O
) O
50 O
mg O
, O
and O
929 O
received O
MYRBETRIQ O
( O
r O
) O
100 O
mg O
once O
daily O
. O

In O
these O
studies O
, O
the O
majority O
of O
the O
patients O
were O
Caucasian O
( O
94 O
% O
) O
, O
and O
female O
( O
72 O
% O
) O
with O
a O
mean O
age O
of O
59 O
years O
( O
range O
18 O
to O
95 O
years O
) O
. O

MYRBETRIQ O
( O
r O
) O
was O
also O
evaluated O
for O
safety O
in O
1632 O
patients O
who O
received O
MYRBETRIQ O
( O
r O
) O
50 O
mg O
once O
daily O
( O
n=812 O
patients O
) O
or O
MYRBETRIQ O
( O
r O
) O
100 O
mg O
( O
n=820 O
patients O
) O
in O
a O
1 O
year O
, O
randomized O
, O
fixed O
dose O
, O
double-blind O
, O
active O
controlled O
, O
safety O
study O
in O
patients O
with O
overactive B-Not_AE_Candidate
bladder I-Not_AE_Candidate
( O
Study O
4 O
) O
. O

Of O
these O
patients O
, O
731 O
received O
MYRBETRIQ O
( O
r O
) O
in O
a O
previous O
12 O
week O
study O
. O

In O
Study O
4 O
, O
1385 O
patients O
received O
MYRBETRIQ O
( O
r O
) O
continuously O
for O
at O
least O
6 O
months O
, O
1311 O
patients O
received O
MYRBETRIQ O
( O
r O
) O
for O
at O
least O
9 O
months O
, O
and O
564 O
patients O
received O
MYRBETRIQ O
( O
r O
) O
for O
at O
least O
1 O
year O
. O

The O
most O
frequent O
adverse O
events O
( O
0.2 O
% O
) O
leading O
to O
discontinuation O
in O
Studies O
1 O
, O
2 O
and O
3 O
for O
the O
25 O
mg O
or O
50 O
mg O
dose O
were O
nausea B-OSE_Labeled_AE
, O
headache B-OSE_Labeled_AE
, O
hypertension B-OSE_Labeled_AE
, O
diarrhea B-OSE_Labeled_AE
, O
constipation B-OSE_Labeled_AE
, O
dizziness B-OSE_Labeled_AE
and O
tachycardia B-OSE_Labeled_AE
. O

Atrial B-OSE_Labeled_AE
fibrillation I-OSE_Labeled_AE
( O
0.2 O
% O
) O
and O
prostate B-OSE_Labeled_AE
cancer I-OSE_Labeled_AE
( O
0.1 O
% O
) O
were O
reported O
as O
serious O
adverse O
events O
by O
more O
than O
1 O
patient O
and O
at O
a O
rate O
greater O
than O
placebo O
. O

Table O
1 O
lists O
adverse O
reactions O
, O
derived O
from O
all O
adverse O
events O
, O
that O
were O
reported O
in O
Studies O
1 O
, O
2 O
and O
3 O
at O
an O
incidence O
greater O
than O
placebo O
and O
in O
1 O
% O
or O
more O
of O
patients O
treated O
with O
MYRBETRIQ O
( O
r O
) O
25 O
mg O
or O
50 O
mg O
once O
daily O
for O
up O
to O
12 O
weeks O
. O

The O
most O
commonly O
reported O
adverse O
reactions O
( O
greater O
than O
2 O
% O
of O
MYRBETRIQ O
( O
r O
) O
patients O
and O
greater O
than O
placebo O
) O
were O
hypertension B-OSE_Labeled_AE
, O
nasopharyngitis B-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
and O
headache B-OSE_Labeled_AE
. O

Table O
1 O
: O
Percentages O
of O
Patients O
with O
Adverse O
Reactions O
, O
Derived O
from O
All O
Adverse O
Events O
, O
Exceeding O
Placebo O
Rate O
and O
Reported O
by O
1 O
% O
or O
More O
Patients O
Treated O
With O
MYRBETRIQ O
( O
r O
) O
25 O
mg O
or O
50 O
mg O
Once O
Daily O
in O
Studies O
1 O
, O
2 O
, O
and O
3 O
Placebo O
( O
% O
) O
MYRBETRIQ O
( O
r O
) O
25 O
mg O
( O
% O
) O
MYRBETRIQ O
( O
r O
) O
50 O
mg O
( O
% O
) O
Number O
of O
Patients O
1380 O
432 O
1375 O
Hypertension B-OSE_Labeled_AE
Includes O
reports O
of O
blood B-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
above I-OSE_Labeled_AE
the I-OSE_Labeled_AE
normal I-OSE_Labeled_AE
range I-OSE_Labeled_AE
, O
and O
BP B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
from I-OSE_Labeled_AE
baseline I-OSE_Labeled_AE
, O
occurring O
predominantly O
in O
subjects O
with O
baseline O
hypertension B-Not_AE_Candidate
. O

7.6 O
11.3 O
7.5 O
Nasopharyngitis B-OSE_Labeled_AE
2.5 O
3.5 O
3.9 O
Urinary B-OSE_Labeled_AE
Tract I-OSE_Labeled_AE
Infection I-OSE_Labeled_AE
1.8 O
4.2 O
2.9 O
Headache B-OSE_Labeled_AE
3.0 O
2.1 O
3.2 O
Constipation B-OSE_Labeled_AE
1.4 O
1.6 O
1.6 O
Upper B-OSE_Labeled_AE
Respiratory I-OSE_Labeled_AE
Tract I-OSE_Labeled_AE
Infection I-OSE_Labeled_AE
1.7 O
2.1 O
1.5 O
Arthralgia B-OSE_Labeled_AE
1.1 O
1.6 O
1.3 O
Diarrhea B-OSE_Labeled_AE
1.3 O
1.2 O
1.5 O
Tachycardia B-OSE_Labeled_AE
0.6 O
1.6 O
1.2 O
Abdominal B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
0.7 O
1.4 O
0.6 O
Fatigue B-OSE_Labeled_AE
1.0 O
1.4 O
1.2 O
Other O
adverse O
reactions O
reported O
by O
less O
than O
1 O
% O
of O
patients O
treated O
with O
MYRBETRIQ O
( O
r O
) O
in O
Studies O
1 O
, O
2 O
, O
or O
3 O
included O
: O
Cardiac B-NonOSE_AE
disorders I-NonOSE_AE
: O
palpitations B-OSE_Labeled_AE
, O
blood B-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
[ O
see O
Clinical O
Pharmacology O
( O
12.2 O
) O
] O
Eye B-NonOSE_AE
disorders I-NonOSE_AE
: O
glaucoma B-OSE_Labeled_AE
[ O
see O
Clinical O
Pharmacology O
( O
12.2 O
) O
] O
Gastrointestinal B-NonOSE_AE
disorders I-NonOSE_AE
: O
dyspepsia B-OSE_Labeled_AE
, O
gastritis B-OSE_Labeled_AE
, O
abdominal B-OSE_Labeled_AE
distension I-OSE_Labeled_AE
Infections B-NonOSE_AE
and I-NonOSE_AE
Infestations I-NonOSE_AE
: O
sinusitis B-OSE_Labeled_AE
, O
rhinitis B-OSE_Labeled_AE
Investigations B-NonOSE_AE
: O
GGT B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
AST B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
ALT B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
LDH B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
Renal B-NonOSE_AE
and I-NonOSE_AE
urinary I-NonOSE_AE
disorders I-NonOSE_AE
: O
nephrolithiasis B-OSE_Labeled_AE
, O
bladder B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
Reproductive B-NonOSE_AE
system I-NonOSE_AE
and I-NonOSE_AE
breast I-NonOSE_AE
disorders I-NonOSE_AE
: O
vulvovaginal B-OSE_Labeled_AE
pruritus I-OSE_Labeled_AE
, O
vaginal B-OSE_Labeled_AE
infection I-OSE_Labeled_AE
Skin B-NonOSE_AE
and I-NonOSE_AE
subcutaneous I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
: O
urticaria B-OSE_Labeled_AE
, O
leukocytoclastic B-OSE_Labeled_AE
vasculitis I-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
, O
pruritus B-OSE_Labeled_AE
, O
purpura B-OSE_Labeled_AE
, O
lip B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
Table O
2 O
lists O
the O
rates O
of O
the O
most O
commonly O
reported O
adverse O
reactions O
, O
derived O
from O
all O
adverse O
events O
in O
patients O
treated O
with O
MYRBETRIQ O
( O
r O
) O
50 O
mg O
for O
up O
to O
52 O
weeks O
in O
Study O
4 O
. O

The O
most O
commonly O
reported O
adverse O
reactions O
( O
> O
3 O
% O
of O
MYRBETRIQ O
( O
r O
) O
patients O
) O
were O
hypertension B-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
headache B-OSE_Labeled_AE
, O
and O
nasopharyngitis B-OSE_Labeled_AE
. O

Table O
2 O
: O
Percentages O
of O
Patients O
with O
Adverse O
Reactions O
, O
Derived O
from O
all O
Adverse O
Events O
, O
Reported O
by O
Greater O
Than O
2 O
% O
of O
Patients O
Treated O
With O
MYRBETRIQ O
( O
r O
) O
50 O
mg O
Once O
Daily O
in O
Study O
4 O
MYRBETRIQ O
( O
r O
) O
50 O
mg O
( O
% O
) O
Active O
Control O
( O
% O
) O
Number O
of O
Patients O
812 O
812 O
Hypertension B-OSE_Labeled_AE
9.2 O
9.6 O
Urinary B-OSE_Labeled_AE
Tract I-OSE_Labeled_AE
Infection I-OSE_Labeled_AE
5.9 O
6.4 O
Headache B-OSE_Labeled_AE
4.1 O
2.5 O
Nasopharyngitis B-OSE_Labeled_AE
3.9 O
3.1 O
Back B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
2.8 O
1.6 O
Constipation B-OSE_Labeled_AE
2.8 O
2.7 O
Dry B-OSE_Labeled_AE
Mouth I-OSE_Labeled_AE
2.8 O
8.6 O
Dizziness B-OSE_Labeled_AE
2.7 O
2.6 O
Sinusitis B-OSE_Labeled_AE
2.7 O
1.5 O
Influenza B-OSE_Labeled_AE
2.6 O
3.4 O
Arthralgia B-OSE_Labeled_AE
2.1 O
2.0 O
Cystitis B-OSE_Labeled_AE
2.1 O
2.3 O
In O
Study O
4 O
, O
in O
patients O
treated O
with O
MYRBETRIQ O
( O
r O
) O
50 O
mg O
once O
daily O
, O
adverse O
reactions O
leading O
to O
discontinuation O
reported O
by O
more O
than O
2 O
patients O
and O
at O
a O
rate O
greater O
than O
active O
control O
included O
: O
constipation B-OSE_Labeled_AE
( O
0.9 O
% O
) O
, O
headache B-OSE_Labeled_AE
( O
0.6 O
% O
) O
, O
dizziness B-OSE_Labeled_AE
( O
0.5 O
% O
) O
, O
hypertension B-OSE_Labeled_AE
( O
0.5 O
% O
) O
, O
dry B-OSE_Labeled_AE
eyes I-OSE_Labeled_AE
( O
0.4 O
% O
) O
, O
nausea B-OSE_Labeled_AE
( O
0.4 O
% O
) O
, O
vision B-OSE_Labeled_AE
blurred I-OSE_Labeled_AE
( O
0.4 O
% O
) O
, O
and O
urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
( O
0.4 O
% O
) O
. O

Serious O
adverse O
events O
reported O
by O
at O
least O
2 O
patients O
and O
exceeding O
active O
control O
included O
cerebrovascular B-OSE_Labeled_AE
accident I-OSE_Labeled_AE
( O
0.4 O
% O
) O
and O
osteoarthritis B-OSE_Labeled_AE
( O
0.2 O
% O
) O
. O

Serum O
ALT B-OSE_Labeled_AE
/AST O
increased I-OSE_Labeled_AE
from O
baseline O
by O
greater O
than O
10-fold O
in O
2 O
patients O
( O
0.3 O
% O
) O
taking O
MYRBETRIQ O
( O
r O
) O
50 O
mg O
, O
and O
these O
markers O
subsequently O
returned O
to O
baseline O
while O
both O
patients O
continued O
MYRBETRIQ O
( O
r O
) O
. O

In O
Study O
4 O
, O
serious O
adverse O
events O
of O
neoplasm O
were O
reported O
by O
0.1 O
% O
, O
1.3 O
% O
, O
and O
0.5 O
% O
of O
patients O
treated O
with O
MYRBETRIQ O
( O
r O
) O
50 O
mg O
, O
MYRBETRIQ O
( O
r O
) O
100 O
mg O
and O
active O
control O
once O
daily O
, O
respectively O
. O

Neoplasms B-OSE_Labeled_AE
reported O
by O
2 O
patients O
treated O
with O
MYRBETRIQ O
( O
r O
) O
100 O
mg O
included O
breast B-OSE_Labeled_AE
cancer I-OSE_Labeled_AE
, O
lung B-OSE_Labeled_AE
neoplasm I-OSE_Labeled_AE
malignant I-OSE_Labeled_AE
and O
prostate B-OSE_Labeled_AE
cancer I-OSE_Labeled_AE
. O

In O
a O
separate O
clinical O
study O
in O
Japan O
, O
a O
single O
case O
was O
reported O
as O
Stevens B-NonOSE_AE
- I-NonOSE_AE
Johnson I-NonOSE_AE
syndrome I-NonOSE_AE
with O
increased B-NonOSE_AE
serum I-NonOSE_AE
ALT I-NonOSE_AE
, O
AST O
and O
bilirubin O
in O
a O
patient O
taking O
MYRBETRIQ O
( O
r O
) O
100 O
mg O
as O
well O
as O
an O
herbal O
medication O
( O
Kyufu O
Gold O
) O
. O

6.2 O
Postmarketing O
Experience O
Because O
these O
spontaneously O
reported O
events O
are O
from O
the O
worldwide O
postmarketing O
experience O
, O
from O
a O
population O
of O
uncertain O
size O
, O
the O
frequency O
of O
events O
and O
the O
role O
of O
mirabegron O
in O
their O
causation O
can O
not O
be O
reliably O
determined O
. O

The O
following O
events O
have O
been O
reported O
in O
association O
with O
mirabegron O
use O
in O
worldwide O
postmarketing O
experience O
: O
Skin B-NonOSE_AE
and I-NonOSE_AE
subcutaneous I-NonOSE_AE
tissue I-NonOSE_AE
: O
angioedema B-OSE_Labeled_AE
of O
the O
face O
, O
lips O
, O
tongue O
, O
and O
larynx O
, O
with O
or O
without O
respiratory B-NonOSE_AE
symptoms I-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
Urologic B-NonOSE_AE
: O
urinary B-OSE_Labeled_AE
retention I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O

